| Michelle R Hensel, MD | |
|
417 First Avenue, Seward, AK 99664 | |
| (907) 224-5205 | |
| Not Available |
| Full Name | Michelle R Hensel |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 28 Years |
| Location | 417 First Avenue, Seward, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154434298 | NPI | - | NPPES |
| P00756937 | Other | AK | RAILROAD MEDICARE PIN |
| MD29533 | Medicaid | AK | |
| DB2364 | Other | AK | RAILROAD MEDICARE GROUP # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4390 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alaska Native Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Native Tribal Health Consortium | 6709780265 | 457 |
News Archive
BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
A breakthrough in human stem cell research, producing embryonic-like cells from umbilical cord blood may substantially speed up the development of treatments for life-threatening illnesses, injuries and disabilities.
A new study has revealed a link between high levels of air pollution and brain shrinkage, a characteristic of Alzheimer's disease.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
According to the consumer group that sponsored "Rx Express" trains to Canada, the U.S. Customs announcement that it will no longer seize prescription drugs being shipped to the U.S. is not the solution that patients need.
› Verified 2 days ago
| Entity Name | Alaska Native Tribal Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437189339 PECOS PAC ID: 6709780265 Enrollment ID: O20031125000772 |
News Archive
BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
A breakthrough in human stem cell research, producing embryonic-like cells from umbilical cord blood may substantially speed up the development of treatments for life-threatening illnesses, injuries and disabilities.
A new study has revealed a link between high levels of air pollution and brain shrinkage, a characteristic of Alzheimer's disease.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
According to the consumer group that sponsored "Rx Express" trains to Canada, the U.S. Customs announcement that it will no longer seize prescription drugs being shipped to the U.S. is not the solution that patients need.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michelle R Hensel, MD 3760 Piper St, Suite 1060, Anchorage, AK 99508-4665 Ph: (907) 212-6522 | Michelle R Hensel, MD 417 First Avenue, Seward, AK 99664 Ph: (907) 224-5205 |
News Archive
BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
A breakthrough in human stem cell research, producing embryonic-like cells from umbilical cord blood may substantially speed up the development of treatments for life-threatening illnesses, injuries and disabilities.
A new study has revealed a link between high levels of air pollution and brain shrinkage, a characteristic of Alzheimer's disease.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
According to the consumer group that sponsored "Rx Express" trains to Canada, the U.S. Customs announcement that it will no longer seize prescription drugs being shipped to the U.S. is not the solution that patients need.
› Verified 2 days ago
Amy Bukac, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 417 First Avenue, Seward, AK 99664 Phone: 907-224-5205 | |
Robert Reeg, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 417 First Ave, Seward, AK 99664 Phone: 907-224-5205 Fax: 907-224-3185 |